866-997-4948(US-Canada Toll Free)

Renal Cell Carcinoma - Pipeline Review, H1 2014

Published By :

Global Markets Direct

Published Date : Mar 2014

Category :

Oncology

No. of Pages : 377 Pages

This report provides comprehensive information on the therapeutic development for Renal Cell Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Renal Cell Carcinoma and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Renal Cell Carcinoma
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
  • The report reviews key players involved in the therapeutics development for Renal Cell Carcinoma and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects 
  • A review of the Renal Cell Carcinoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Renal Cell Carcinoma pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Renal Cell Carcinoma
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Renal Cell Carcinoma pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Content

Table of Contents 2
List of Tables 7
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Renal Cell Carcinoma Overview 11
Therapeutics Development 12
Pipeline Products for Renal Cell Carcinoma - Overview 12
Pipeline Products for Renal Cell Carcinoma - Comparative Analysis 13
Renal Cell Carcinoma - Therapeutics under Development by Companies 14
Renal Cell Carcinoma - Therapeutics under Investigation by Universities/Institutes 20
Renal Cell Carcinoma - Pipeline Products Glance 22
Late Stage Products 22
Clinical Stage Products 23
Early Stage Products 24
Unknown Stage Products 25
Renal Cell Carcinoma - Products under Development by Companies 26
Renal Cell Carcinoma - Products under Investigation by Universities/Institutes 31
Renal Cell Carcinoma - Companies Involved in Therapeutics Development 32
Bristol-Myers Squibb Company 32
Boehringer Ingelheim GmbH 33
Kyowa Hakko Kirin Co., Ltd. 34
Amgen Inc. 35
Eli Lilly and Company 36
GlaxoSmithKline plc 37
Seattle Genetics, Inc. 38
Genentech, Inc. 39
Agenus, Inc. 40
Merck & Co., Inc. 41
Celltrion, Inc. 42
Astellas Pharma Inc. 43
ImmunoGen, Inc. 44
Ono Pharmaceutical Co., Ltd. 45
Pfizer Inc. 46
Taiho Pharmaceutical Co., Ltd. 47
Onyx Pharmaceuticals, Inc. 48
Bayer AG 49
Advaxis, Inc. 50
Hemispherx Biopharma, Inc. 51
Celldex Therapeutics, Inc. 52
Active Biotech AB 53
Lorus Therapeutics Inc. 54
Lpath, Inc. 55
Bionomics Limited 56
Flamel Technologies S.A. 57
Mologen AG 58
Threshold Pharmaceuticals, Inc. 59
Colby Pharmaceutical Company 60
Wilex AG 61
Glycotope GmbH 62
Hutchison MediPharma Limited 63
Cerulean Pharma, Inc. 64
Deciphera Pharmaceuticals, LLC 65
Jennerex Biotherapeutics, Inc. 66
Advenchen Laboratories, LLC 67
Omeros Corporation 68
Vaccinogen, Inc. 69
Oncolys BioPharma Inc. 70
Immunocore Limited 71
Immune Design Corp. 72
InteRNA Technologies B.V. 73
Taiwan Liposome Company, Ltd. 74
Xcovery, Inc. 75
CureTech Ltd. 76
KAHR medical Ltd. 77
Jiangsu Chia-tai Tianqing Pharmaceutical Co., Ltd. 78
Elara Pharmaceuticals GmbH 79
n.v. BRUCELLS s.a. 80
Medical Enzymes AG 81
Incuron, LLC 82
BiOrion Technologies B.V. 83
SentoClone International AB 84
Ampio Pharmaceuticals, Inc. 85
Karyopharm Therapeutics, Inc. 86
X-BODY BioSciences, Inc. 87
Immunservice GmbH 88
Immunicum AB 89
Conkwest, Inc. 90
Panacela Labs, Inc. 91
AbbVie Inc. 92
MediaPharma s.r.l. 93
OncoMax 94
Renal Cell Carcinoma - Therapeutics Assessment 95
Assessment by Monotherapy Products 95
Assessment by Combination Products 96
Assessment by Target 97
Assessment by Mechanism of Action 103
Assessment by Route of Administration 109
Assessment by Molecule Type 112
Drug Profiles 115
pazopanib hydrochloride - Drug Profile 115
tivozanib - Drug Profile 119
sorafenib tosylate - Drug Profile 122
axitinib - Drug Profile 126
sunitinib malate - Drug Profile 129
R-100 - Drug Profile 133
girentuximab - Drug Profile 135
nivolumab - Drug Profile 137
pazopanib hydrochloride - Drug Profile 141
naptumomab estafenatox - Drug Profile 145
rilotumumab - Drug Profile 147
regorafenib - Drug Profile 149
linifanib - Drug Profile 151
tasquinimod - Drug Profile 153
LT-1009 - Drug Profile 155
carfilzomib - Drug Profile 159
pexastimogene devacirepvec - Drug Profile 162
nintedanib - Drug Profile 164
GlutaDON - Drug Profile 166
pidilizumab - Drug Profile 168
CRLX-101 - Drug Profile 170
BNC-105 - Drug Profile 172
TLC-388 - Drug Profile 174
(tegafur + gimeracil + oteracil) - Drug Profile 176
Pulmoleukin - Drug Profile 179
RG-7446 - Drug Profile 180
AL-3818 - Drug Profile 182
RG-7446 + bevacizumab - Drug Profile 183
axitinib - Drug Profile 184
aldesleukin biobetter - Drug Profile 187
cetuximab biobetter - Drug Profile 188
TH-302 - Drug Profile 189
OncoVAX - Drug Profile 196
DC-CIK - Drug Profile 198
Wilms Tumor Gene mRNA Transfected Autologous Dendritic Cell Vaccine - Drug Profile 200
MGN-1601 - Drug Profile 201
pembrolizumab - Drug Profile 203
Allogeneic Dendritic Cell Cancer Vaccine - Drug Profile 205
MDX-1203 - Drug Profile 207
varlilumab - Drug Profile 208
MKC-1106-PP - Drug Profile 209
CST-101 - Drug Profile 211
SentoClone - Drug Profile 212
MDX-1411 - Drug Profile 214
AGS-16M8F - Drug Profile 215
hydroxychloroquine - Drug Profile 216
LY-2875358 - Drug Profile 217
X-82 - Drug Profile 218
IMGN-853 - Drug Profile 219
AMG-172 - Drug Profile 220
HMPL-504 - Drug Profile 222
AGS-16C3F - Drug Profile 224
CB-839 - Drug Profile 225
AM-0010 - Drug Profile 226
Cytokine-induced Killer Cells - Drug Profile 227
ID-G305 - Drug Profile 228
PSMA DNA Vaccine - Drug Profile 230
MDNA-55 - Drug Profile 231
LOR-1284 - Drug Profile 232
CDX-014 - Drug Profile 233
OBP-801 - Drug Profile 234
CBL-0137 - Drug Profile 235
KAHR-101 - Drug Profile 236
bevacizumab biosimilar - Drug Profile 237
BCL-004 - Drug Profile 238
ImmTAC Targeting MAGE-A3 HLA-A1 - Drug Profile 239
AL-8326 - Drug Profile 240
Mobilan - Drug Profile 241
AL-2846 - Drug Profile 243
NCE-001 - Drug Profile 244
Anti-Angiogenic microRNA-Based Therapeutic For Cancer - Drug Profile 245
CYP-0150 - Drug Profile 246
BC-2059 - Drug Profile 247
Vascular Endothelial Growth Factor-165B - Drug Profile 248
doxorubicin liposomal - Drug Profile 249
BOT-191 - Drug Profile 250
OMRCA-01 - Drug Profile 251
KPT-251 - Drug Profile 253
SGN-CD70A - Drug Profile 254
Immunotherapy For Renal Cancer - Drug Profile 255
ELR-510444 - Drug Profile 256
naftopidil - Drug Profile 257
DCC-3014 - Drug Profile 258
Lm-LLO-CA9 - Drug Profile 259
MPHE-001B - Drug Profile 261
ImmTAC Targeting MAGE A3 - Drug Profile 262
Small Molecules to Activate AMPK for Renal Cell Carcinoma - Drug Profile 263
Small Molecule Targeting GPR65 for Cancer and Inflammatory Disorders - Drug Profile 264
XB-2202 - Drug Profile 265
Syrbactins - Drug Profile 266
rintatolimod - Drug Profile 267
Renal Cell Carcinoma - Recent Pipeline Updates 269
Renal Cell Carcinoma - Dormant Projects 359
Renal Cell Carcinoma - Discontinued Products 361
Renal Cell Carcinoma - Product Development Milestones 362
Featured News & Press Releases 362

Appendix 370
Methodology 370
Coverage 370
Secondary Research 370
Primary Research 370
Expert Panel Validation 370
Contact Us 371
Disclaimer 371

List of Table


Number of Products under Development for Renal Cell Carcinoma, H1 2014 18
Number of Products under Development for Renal Cell Carcinoma - Comparative Analysis, H1 2014 19
Number of Products under Development by Companies, H1 2014 21
Number of Products under Development by Companies, H1 2014 (Contd..1) 22
Number of Products under Development by Companies, H1 2014 (Contd..2) 23
Number of Products under Development by Companies, H1 2014 (Contd..3) 24
Number of Products under Development by Companies, H1 2014 (Contd..4) 25
Number of Products under Investigation by Universities/Institutes, H1 2014 27
Comparative Analysis by Late Stage Development, H1 2014 28
Comparative Analysis by Clinical Stage Development, H1 2014 29
Comparative Analysis by Early Stage Development, H1 2014 30
Comparative Analysis by Unknown Stage Development, H1 2014 31
Products under Development by Companies, H1 2014 32
Products under Development by Companies, H1 2014 (Contd..1) 33
Products under Development by Companies, H1 2014 (Contd..2) 34
Products under Development by Companies, H1 2014 (Contd..3) 35
Products under Development by Companies, H1 2014 (Contd..4) 36
Products under Investigation by Universities/Institutes, H1 2014 37
Renal Cell Carcinoma - Pipeline by Bristol-Myers Squibb Company, H1 2014 38
Renal Cell Carcinoma - Pipeline by Boehringer Ingelheim GmbH, H1 2014 39
Renal Cell Carcinoma - Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2014 40
Renal Cell Carcinoma - Pipeline by Amgen Inc., H1 2014 41
Renal Cell Carcinoma - Pipeline by Eli Lilly and Company, H1 2014 42
Renal Cell Carcinoma - Pipeline by GlaxoSmithKline plc, H1 2014 43
Renal Cell Carcinoma - Pipeline by Seattle Genetics, Inc., H1 2014 44
Renal Cell Carcinoma - Pipeline by Genentech, Inc., H1 2014 45
Renal Cell Carcinoma - Pipeline by Agenus, Inc., H1 2014 46
Renal Cell Carcinoma - Pipeline by Merck & Co., Inc., H1 2014 47
Renal Cell Carcinoma - Pipeline by Celltrion, Inc., H1 2014 48
Renal Cell Carcinoma - Pipeline by Astellas Pharma Inc., H1 2014 49
Renal Cell Carcinoma - Pipeline by ImmunoGen, Inc., H1 2014 50
Renal Cell Carcinoma - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2014 51
Renal Cell Carcinoma - Pipeline by Pfizer Inc., H1 2014 52
Renal Cell Carcinoma - Pipeline by Taiho Pharmaceutical Co., Ltd., H1 2014 53
Renal Cell Carcinoma - Pipeline by Onyx Pharmaceuticals, Inc., H1 2014 54
Renal Cell Carcinoma - Pipeline by Bayer AG, H1 2014 55
Renal Cell Carcinoma - Pipeline by Advaxis, Inc., H1 2014 56
Renal Cell Carcinoma - Pipeline by Hemispherx Biopharma, Inc., H1 2014 57
Renal Cell Carcinoma - Pipeline by Celldex Therapeutics, Inc., H1 2014 58
Renal Cell Carcinoma - Pipeline by Active Biotech AB, H1 2014 59
Renal Cell Carcinoma - Pipeline by Lorus Therapeutics Inc., H1 2014 60
Renal Cell Carcinoma - Pipeline by Lpath, Inc., H1 2014 61
Renal Cell Carcinoma - Pipeline by Bionomics Limited, H1 2014 62
Renal Cell Carcinoma - Pipeline by Flamel Technologies S.A., H1 2014 63
Renal Cell Carcinoma - Pipeline by Mologen AG, H1 2014 64
Renal Cell Carcinoma - Pipeline by Colby Pharmaceutical Company, H1 2014 65
Renal Cell Carcinoma - Pipeline by Colby Pharmaceutical Company, H1 2014 66
Renal Cell Carcinoma - Pipeline by Wilex AG, H1 2014 67
Renal Cell Carcinoma - Pipeline by Hutchison MediPharma Limited, H1 2014 69
Renal Cell Carcinoma - Pipeline by Cerulean Pharma, Inc., H1 2014 70
Renal Cell Carcinoma - Pipeline by Deciphera Pharmaceuticals, LLC, H1 2014 71
Renal Cell Carcinoma - Pipeline by Jennerex Biotherapeutics, Inc., H1 2014 72
Renal Cell Carcinoma - Pipeline by Advenchen Laboratories, LLC, H1 2014 73
Renal Cell Carcinoma - Pipeline by Omeros Corporation, H1 2014 74
Renal Cell Carcinoma - Pipeline by Vaccinogen, Inc., H1 2014 75
Renal Cell Carcinoma - Pipeline by Oncolys BioPharma Inc., H1 2014 76
Renal Cell Carcinoma - Pipeline by Immunocore Limited, H1 2014 77
Renal Cell Carcinoma - Pipeline by Immune Design Corp., H1 2014 78
Renal Cell Carcinoma - Pipeline by InteRNA Technologies B.V., H1 2014 79
Renal Cell Carcinoma - Pipeline by Taiwan Liposome Company, Ltd., H1 2014 80
Renal Cell Carcinoma - Pipeline by Xcovery, Inc., H1 2014 81
Renal Cell Carcinoma - Pipeline by CureTech Ltd., H1 2014 82
Renal Cell Carcinoma - Pipeline by KAHR medical Ltd., H1 2014 83
Renal Cell Carcinoma - Pipeline by Jiangsu Chia-tai Tianqing Pharmaceutical Co., Ltd., H1 2014 84
Renal Cell Carcinoma - Pipeline by Elara Pharmaceuticals GmbH, H1 2014 85
Renal Cell Carcinoma - Pipeline by n.v. BRUCELLS s.a., H1 2014 86
Renal Cell Carcinoma - Pipeline by Medical Enzymes AG, H1 2014 87
Renal Cell Carcinoma - Pipeline by Incuron, LLC, H1 2014 88
Renal Cell Carcinoma - Pipeline by BiOrion Technologies B.V., H1 2014 89
Renal Cell Carcinoma - Pipeline by SentoClone International AB, H1 2014 90
Renal Cell Carcinoma - Pipeline by Ampio Pharmaceuticals, Inc., H1 2014 91
Renal Cell Carcinoma - Pipeline by Karyopharm Therapeutics, Inc., H1 2014 92
Renal Cell Carcinoma - Pipeline by X-BODY BioSciences, Inc., H1 2014 93
Renal Cell Carcinoma - Pipeline by Immunservice GmbH, H1 2014 94
Renal Cell Carcinoma - Pipeline by Immunicum AB, H1 2014 95
Renal Cell Carcinoma - Pipeline by Conkwest, Inc., H1 2014 96
Renal Cell Carcinoma - Pipeline by Panacela Labs, Inc., H1 2014 97
Renal Cell Carcinoma - Pipeline by AbbVie Inc., H1 2014 98
Renal Cell Carcinoma - Pipeline by MediaPharma s.r.l., H1 2014 99
Renal Cell Carcinoma - Pipeline by OncoMax, H1 2014 100
Assessment by Monotherapy Products, H1 2014 101
Assessment by Combination Products, H1 2014 102
Number of Products by Stage and Target, H1 2014 105
Number of Products by Stage and Mechanism of Action, H1 2014 111
Number of Products by Stage and Route of Administration, H1 2014 117
Number of Products by Stage and Molecule Type, H1 2014 120
Renal Cell Carcinoma Therapeutics - Recent Pipeline Updates, H1 2014 275
Renal Cell Carcinoma - Dormant Projects, H1 2014 365
Renal Cell Carcinoma - Discontinued Products, H1 2014 367

List of Chart


Number of Products under Development for Renal Cell Carcinoma, H1 2014 18
Number of Products under Development for Renal Cell Carcinoma - Comparative Analysis, H1 2014 19
Number of Products under Development by Companies, H1 2014 20
Number of Products under Investigation by Universities/Institutes, H1 2014 26
Comparative Analysis by Late Stage Development, H1 2014 28
Comparative Analysis by Clinical Stage Development, H1 2014 29
Comparative Analysis by Early Stage Products, H1 2014 30
Assessment by Monotherapy Products, H1 2014 101
Number of Products by Top 10 Target, H1 2014 103
Number of Products by Stage and Top 10 Target, H1 2014 104
Number of Products by Top 10 Mechanism of Action, H1 2014 109
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 110
Number of Products by Top 10 Route of Administration, H1 2014 115
Number of Products by Stage and Top 10 Route of Administration, H1 2014 116
Number of Products by Top 10 Molecule Type, H1 2014 118
Number of Products by Stage and Top 10 Molecule Type, H1 2014 119

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *